On September 26, 2013 the manufacturer Eli Lilly announced that its Phase III study for<unk>  failed to hit its primary endpoint on progression-free survival among women with metastatic breast cancer. In June 2014, a phase III trial of the drug reported it failed to improve overall survival in liver cancer. In Feb 2016 it was reported that a phase II trial of adding<unk>  to docetaxel improved progression-free survival (PFS) compared with docetaxel alone in locally advanced or metastatic urothelial carcinoma. It is now in the RANGE phase III trial for this indication. Between 2016 and 2018, 26 hospitals in Italy conducted a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial to evaluate the safety and effectiveness of the anti-VEGFR-2 antibody<unk>  combined with gemcitabine in patients with pretreated pleural mesothelioma. Combining<unk>  to standard second line gemcitabine significantly improved overall survival after failure of first-line chemotherapy, with a favourable safety profile.
Ramucirumab
Ustekinumab
Emapalumab
Olaratumab
Evolocumab
Avelumab
Anifrolumab
Burosumab